{
  "docId": "019de072-b09f-7797-83e5-c925df87e1b3",
  "docSlug": "fb96dc8e32131cd826524e728a742819",
  "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 36 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 36,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "context",
  "function": "establish_context",
  "density": "balanced",
  "nDataPoints": 4,
  "notes": "BTC stands for Biliary Tract Cancer. The slide contrasts established standard-of-care regimens with the lack of efficacy for taxanes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-b09f-7797-83e5-c925df87e1b3/23",
  "deckHref": "/decks/019de072-b09f-7797-83e5-c925df87e1b3",
  "deckJsonHref": "/decks/019de072-b09f-7797-83e5-c925df87e1b3.json",
  "deckAnchorHref": "/decks/019de072-b09f-7797-83e5-c925df87e1b3#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.45,
        "x": 0.52,
        "y": 0.18
      },
      "kind": "list",
      "text": "Taxanes: Neither paclitaxel nor docetaxel are recommended by NCCN; Paclitaxel: No responses in a 15 patient first-line study [Jones, et al. (1996)]; Docetaxel: No responses in a 17 patient first-and second-line study [Pazdur, et al. (1999)]; Nab-Paclitaxel is under investigation, but preferred first line regimen is Gem/Cis per NCCN Guidelines",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "13554698-0d25-4ef4-bf35-8ca332edb81c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.03,
        "y": 0.18
      },
      "kind": "list",
      "text": "NCCN Guidelines: First Line: Gem/Cis doublet (26.1% ORR, 3.6 month increase in median OS vs. Gem alone (HR=0.64), Valle, et al. (2010)); Second-line: FOLFOX (5% ORR, 0.9 month increase in median OS vs. supportive care (HR=0.69), Lamarca, et al. (2021))",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b05b235f-24f3-41e7-9c9c-88e37303db71",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.42,
        "x": 0.29,
        "y": 0.06
      },
      "kind": "title",
      "text": "Chemotherapy in BTC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec8801ec-1cda-4646-9611-718858417aee",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "7b596983-fa97-40c8-88b9-d70d55727f85",
      "evidence": "The slide contains a list/bullet points with chemotherapy information.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 24,
      "from": 16,
      "beatId": "f6eca836-c306-461a-9e22-743547581023",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "Slides 16-24 agitate the problem, emphasizing the limitations of current treatments.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 24,
      "from": 16,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "05173e5b-462d-46a8-b79a-b596b9de2b77",
      "evidence": "Slides 16-24 highlight the limitations of current treatments, implying the cost of inaction.",
      "position": 0,
      "objective": "What is the cost of not addressing the unmet needs in BTC treatment?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}